MaxCyte, Inc.
MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assaysā¦ read more
Healthcare
Medical Devices
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.07
Price+1.43%
$0.02
1Y
Price
Market Cap
$114.085m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-38.4%
EBITDA Margin-49.2%
Net Profit Margin-86.9%
Free Cash Flow Margin-38.4%
EBITDA Margin-49.2%
Net Profit Margin-86.9%
Free Cash Flow MarginRevenue
$32.287m
-2.2%
1y CAGR-7.7%
3y CAGR-7.5%
5y CAGREarnings
-$39.119m
+12.4%
1y CAGR-1.5%
3y CAGR-16.4%
5y CAGREPS
-$0.37
+11.9%
1y CAGR-0.4%
3y CAGR-24.0%
5y CAGRBook Value
$167.886m
$194.473m
Assets$26.587m
Liabilities$17.487m
DebtDebt to Assets
9.0%
-0.5x
Debt to EBITDAFree Cash Flow
-$29.505m
+18.4%
1y CAGR-6.8%
3y CAGR+0.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company